PrismaLung+ enables ECCO2R therapy

PrismaLung+ Filterset

Deliver ECCO2R therapy on the PrisMax platform, either as stand-alone CO2 removal therapy or in combination with CRRT and blood purification.

Maximize ECCO2R performance

The PrismaLung+ blood-gas exchanger was specifically designed to enable CO2 removal with therapy-specific software on the PrisMax System. 

The PrismaLung+ blood-gas exchanger is intended for patients with increased levels of CO2 in their blood and with a body weight greater than or equal to 30 kg (66 Ib).1

Compatible Products

Solutions

Support management of acute respiratory dysfunction with ECCO2R

Extracorporeal carbon dioxide removal (ECCO2R) therapy removes CO2 from a patient’s blood to effectively manage acute hypercapnia and respiratory acidosis to facilitate the use of lung-protective ventilation (LPV) or ultra lung-protective ventilation (ULPV) in patients with ARDS2-5 as well as enable the use of NIV strategies in patients with aeCOPD, which may reduce the need for intubation. For patients with multiple organ dysfunction, the therapy can also be integrated with other therapies delivered on a single platform.

PrismaLung+ enables ECCO2R therapy

Deliver ECCO2R as standalone or in combination with other therapies6

ECCO₂R

Deliver stand-alone ECCO2R to support management of acute respiratory dysfunction.

ECCO₂R and CRRT combined

Combine therapies to support management of acute respiratory dysfunction and acute kidney injury. 

ECCO₂R, CRRT and blood purification for sepsis management simultaneously

Add blood purification for sepsis management to simultaneously support management of acute respiratory dysfunction and AKI in patients who may benefit from removal of endotoxins and inflammatory mediators – all with one vascular access point.

Example of ECCO2R and CRRT setup

The PrismaLung+ blood-gas exchanger can deliver standalone ECCO2R therapy or in combination with CRRT.1

Prismalung+ example of ECCO2R and CRRT setup

Optimize CO₂ removal with smaller membrane for risk management

The PrismaLung+ blood-gas exchanger delivers CO2 removal equivalent to that of a device with a larger surface area, while addressing risks that may be associated with extracorporeal therapies: 

  • Smaller membrane size to help reduce clotting risk
  • Lower extracorporeal blood volume

An in vitro study shows that at the same blood flow rates and the same initial PaCO2 levels, the PrismaLung+ blood-gas exchanger (0.8 m2) provides similar CO2 removal rate performance when compared to a much larger membrane.7

The PrismaLung+ blood-gas exchanger

The PrismaLung+ blood-gas exchanger removes CO2 at blood flow rates ≤ 450 mL/min as effectively as a device with a larger surface area.7

The PrismaLung+ blood-gas exchanger removes CO2 at blood flow rates ≤ 450 mL/min as effectively as a device with a larger surface area.7

Vascular access performance

By operating at blood flow rates similar to CRRT and using the same vascular access, the PrismaLung+ blood-gas exchanger limits the invasiveness of ECCO2R therapy compared to mid-flow ECCO2R and vv-ECMO. The PrismaLung+ blood-gas exchanger works with any brand catheter, and can be used with Vantive’s GamCath GDHK-1320 catheter, which has demonstrated one of the best access and return pressure performances at various blood flow rates when compared to other brands and designs including bigger catheter sizes (13, 14 and 15 FR).8

  • With the PrismaLung+ blood-gas exchanger, operating blood-flow rates do not exceed 450 ml/min1 allowing ECCO2R to be performed using 13FR catheters, which are typically used for CRRT 
  • ECCO2R and CRRT can be run simultaneously using a single catheter, avoiding the need for multiple access sites
  • The PrismaLung+ blood-gas exchanger with the PrisMax 2 System allows the combination of ECCO2R with CRRT and blood purification for sepsis management in one extracorporeal circuit, thus reducing the total extracorporeal blood volume compared to running the therapies independently 

Maintain patient blood temperature6

When integrated with the PrisMax System, the PrismaLung+ blood-gas exchanger uses the TherMax blood warmer to provide an advanced source of support for efficient and easy patient blood warming. Automatic blood heating adjustment helps meet the prescribed return blood temperature independently from blood flow rates and therapy interruptions.

Optimized ECCO₂R delivery with smart efficiencies

Integrate ECCO2R therapy into an existing CRRT setup with the PrismaLung+ blood-gas exchanger on the PrisMax System and reduce the need for additional capital expenditure and monitor maintenance while minimizing staff training requirements.

Reduce the need for additional investments and monitor maintenance

Run all therapies (CRRT, TPE, ECCO2R, blood purification for sepsis management) and modalities (SCUF, CVVH, CVVHD, CVVHDF) using just one monitor with the PrisMax System.

Optimize staff workload and training

Streamline ECCO2R treatment setup with step-by-step software guidance through the intuitive PrisMax interface. Providing a setup and implementation routine similar to CRRT enables easy integration of the therapy with limited training effort. 

 The PrismaLung+ blood-gas exchanger is easily added to the CRRT set, and the whole set is automatically one-step primed which means interactions during setup is similar to CRRT.

Enhance overall treatment accuracy

Help improve patient fluid balance accuracy with Vantive’s patented software algorithm estimating normal phenomenon of water evaporation during ECCO2R treatment.6

Related products

Learn more

Speak with a Vantive representative to ask questions and learn how we can help you address challenges in your ICU.

Contact us

Acronyms

ARDS = acute respiratory distress syndrome
aeCOPD = acute exacerbation of chronic obstructive pulmonary disease
LPV = lung protective ventilation
ULPV = ultraprotective lung protective ventilation
VILI = ventilation induced lung injury
NIV = non-invasive ventilation

Important Safety Information

Please click here for important safety information.

Vantive, GamCath, Oxiris, PrismaLung+, PrisMax and TherMax are trademarks of Vantive Health LLC or its affiliates.

 

References

  1. Vantive Health LLC. PrismaLung+ Instructions for Use. May 2021.

  2. Fanelli V, Ranieri MV, Mancebo J, et al. Feasibility and safety of low-flow extracorporeal carbon dioxide removal to facilitate ultra-protective ventilation in patients with moderate acute respiratory distress sindrome. Crit Care. 2016;20:36.

  3. Schmidt M, Jaber S, Zogheib E, Godet T, Capellier G, Combes A. Feasibility and safety of low-flow extracorporeal CO2 removal managed with a renal replacement platform to enhance lung-protective ventilation of patients with mild-to-moderate ARDS. Crit Care. 2018;22(1):122.

  4. Winiszewski H, Aptel F, Belon F, et al. Daily use of extracorporeal CO2 removal in a critical care unit: indications and results. J Intensive Care. 2018;6:36.

  5. Combes A, Fanelli V, Pham T, Ranieri VM; European Society of Intensive Care Medicine Trials Group and the “Strategy of Ultra-Protective lung ventilation with Extracorporeal CO2 Removal for New-Onset moderate to severe ARDS” (SUPERNOVA) investigators. Feasibility and safety of extracorporeal CO2 removal to enhance protective ventilation in acute respiratory distress syndrome: the SUPERNOVA study. Intensive Care Med. 2019;45(5):592-600.

  6. Vantive Health LLC. PrisMax Operator’s Manual AW8046. May, 2024.

  7. Hospach I, Goldstein J, Harenski K, et al. In vitro characterization of PrismaLung+: a novel ECCO2R device. Intensive Care Med Exp. 2020;8(1):14.

  8. Vantive Health LLC. In-vitro Flow Comparison for CRRT Catheter. 2019. Internal documentation.